Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels

Bone Marrow Transplantation

Volumn 17, Issue 4, 1996, Pages 491-495

  Demirer, T ^a,b   Buckner, C D ^a   Appelbaum, F R ^a   Bensinger, W I ^a   Sanders, J ^a   Lambert, K ^a   Clift, R ^a   Fefer, A ^a   Storb, R ^a   Slattery, J T ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

BMT; Busulfan; CML; Cyclophosphamide; Plasma levels

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; PHENYTOIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANALYTICAL ERROR; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLADDER DISEASE; BONE MARROW TRANSPLANTATION; CARDIOTOXICITY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG TOXICITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RELAPSE; SEIZURE; SKIN TOXICITY; SURVIVAL; WHOLE BODY RADIATION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BUSULFAN; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID; LIFE TABLES; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 0029866142     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Petersen FB. Buckner CD, Appelbaum FR et al. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. Bone Marrow Transplant 1989; 4: 617-623.
2. Petersen FB, Lynch MHE, Clift RA et al. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 1993; 11: 1353-1360.
3. Slattery JT, Sanders JE, Buckner CD et al Graft-rejection and toxicity following bone marrow transplantation in relation to busutfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
4. Hassan M, Oberg G, Ehrsson H. Pharmacokinetic and metabolic studies of high-dose busulfan in adults. Eur J Clin Pharmacol 1989; 36: 525-530.
5. Grochow LB, Jones RJ, Brundrett et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
6. Meresse V, Hartmann O, Vassal G et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 chiidren, Bone Marrow Transplant 1992: 10: 135-141.
7. Demirer T, Buckner CD, Appelbaum FR et al. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation for advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfann based on targeted plasma levels. Bone Marrow Transplant 1996; 17: 341-346.
8. Lam W-C, Order SE, Thomas ED. Uniformity and standardization of single and opposing cobalt 60 sources for total body irradiation. Int J Radiat Oncol Biol Phys 1980; 6: 245-250.
9. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
10. Crawford SW. Critical care and respiratory failure. In: Forman SJ, Blume K, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, MA, 1994, pp 513-526.
11. Shuhart MC, McDonald GB, Gastrointestinal and hepatic complications. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, MA, 1994, pp 454-481.
12. Benyunes MC, Buckner CD, Fefer A et al. Interleukin 2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12: 159-163.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Clift RA. Marrow transplantation for chronic myeloid leukemia. In: Buckner CD (ed). Technical and Biological Components of Marrow Transplantation. Kluwer Academic: Norwell, MA, 1995, pp 1-42.
15. 1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. New Engl J Med 1979; 300: 333-337.
16. Fefer A, Cheever MA, Greenberg PD et al. Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. New Engl J Med 1982; 306: 63-68.